| Page 6 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies

Author(s): 
Panse J, Han B, Cermak J, Gonzalez Fernandez FA, Gotoh A, Kulasekararaj AG, Kyselova O, Sahin F, Scheinberg P, Schrezenmeier H, Straetmans N, Ueda Y, Chang AC, Gentile B, Stefani J, Uguen M, Röth A
Primary Author: 
Panse J
Journal Title: 
Annals of Hematology
Original Publication Date: 
Jun 2025
Bone Marrow Disease(s): 

Impact of HLA alloimmunization on clinical outcomes of severe aplastic anemia treated with immunosuppressive therapy

Author(s): 
Durrani J, Chen LN, Shalhoub RN, Baez V, Glass J, Cha NR, Ma X, Wu Z, Gao S, Lotter J, Rios O, Wu CO, Flegel WA, Young NS, Groarke EM, Patel BA
Primary Author: 
Durrani J
Journal Title: 
Blood Advances
Original Publication Date: 
Jun 2025

Immune

Bone Marrow Disease(s): 

Towards graft- versus-host disease-free alternative donor transplant platforms for patients with acquired aplastic anemia

Author(s): 
Oved JH, Bacigalupo A, DeZern AE
Primary Author: 
Oved JH
Journal Title: 
Haematologica
Original Publication Date: 
May 2025

Hematopoietic stem cell transplantation is a well-established treatment option for acquired

Bone Marrow Disease(s): 

What are the most important quality of life domains for patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria?

Author(s): 
Taylor KJ, Singer S, Langemeijer S, Kelly RJ, Arnold L, Panse J, Patriquin CJ, Nishimura JI, Piggin M, Burmester PO
Primary Author: 
Taylor KJ
Journal Title: 
Annals of Hematology
Original Publication Date: 
May 2025
Bone Marrow Disease(s): 

Disease Burden at the Time of Transplantation Is a Primary Predictor of Outcomes in Pediatric MDS: A Single-Center Experience

Author(s): 
Dahlberg A, Stevenson P, Bhatt NS, Burroughs L, Carpenter PA, Summers C, Tarlock K, Thakar MS, Milano F, Deeg HJ, Bleakley M
Primary Author: 
Dahlberg A
Journal Title: 
Cancers
Original Publication Date: 
May 2025

Background: Hematopoietic cell transplantation (HCT) remains the only curative therapy for pediatric myelodysplastic syndrome (MDS) in all but rare cases. While HCT outcomes for pediatric MDS are similar across the largest registry and single-center trials, factors identified as contributing to inferior outcomes vary from study to study. We performed an analysis to provide more clarity on the prognostic implications of disease characteristics, including blast burden and cytogenetic abnormalities, in the current era.

Bone Marrow Disease(s):